JP2014521353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521353A5 JP2014521353A5 JP2014524110A JP2014524110A JP2014521353A5 JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5 JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- present
- culture
- hela cells
- roller bottle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515724P | 2011-08-05 | 2011-08-05 | |
| US61/515,724 | 2011-08-05 | ||
| PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521353A JP2014521353A (ja) | 2014-08-28 |
| JP2014521353A5 true JP2014521353A5 (enExample) | 2016-10-20 |
| JP6243333B2 JP6243333B2 (ja) | 2017-12-06 |
Family
ID=46650950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524110A Active JP6243333B2 (ja) | 2011-08-05 | 2012-08-03 | ワクシニアウィルスの生成のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9719105B2 (enExample) |
| EP (1) | EP2739293B1 (enExample) |
| JP (1) | JP6243333B2 (enExample) |
| KR (1) | KR102022952B1 (enExample) |
| CN (1) | CN103732236B (enExample) |
| AU (1) | AU2012294606B2 (enExample) |
| BR (1) | BR112014000787B1 (enExample) |
| CA (1) | CA2841831C (enExample) |
| DK (1) | DK2739293T3 (enExample) |
| ES (1) | ES2813413T3 (enExample) |
| PL (1) | PL2739293T3 (enExample) |
| WO (1) | WO2013022764A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| AU2016313969B2 (en) | 2015-06-19 | 2021-12-23 | Sillajen, Inc. | Compositions and methods for viral embolization |
| CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰（天津）生物制药有限公司 | HeLa-F细胞及其用途 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| CA3045228C (en) | 2016-12-28 | 2024-01-02 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| CN118892540A (zh) | 2017-04-21 | 2024-11-05 | 新罗杰股份有限公司 | 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法 |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| JP7625519B2 (ja) * | 2018-11-21 | 2025-02-03 | カリヴィル イムノセラピューティクス， インコーポレイテッド | ウイルスの製造 |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| CN112143693B (zh) * | 2019-06-28 | 2024-12-27 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2021261892A1 (ko) * | 2020-06-22 | 2021-12-30 | 코오롱생명과학 주식회사 | 부유세포를 이용한 백시니아 바이러스의 대량생산방법 |
| KR20230038496A (ko) | 2020-07-13 | 2023-03-20 | 트랜스진 | 면역 억제의 치료 |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术（上海）股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| KR20250052416A (ko) | 2022-08-18 | 2025-04-18 | 트랜스진 | 키메라 폭스바이러스 |
| AU2024236322A1 (en) * | 2023-03-10 | 2025-08-21 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| WO2004014314A2 (en) | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| ATE412737T1 (de) * | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| CA2662569C (en) * | 2006-08-07 | 2017-01-03 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Process for preparing live smallpox vaccine |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| WO2011017050A1 (en) | 2009-07-28 | 2011-02-10 | Corning Incorporated | Synthetic microcarriers for culturing cells |
| KR101838472B1 (ko) * | 2009-09-14 | 2018-03-15 | 신라젠(주) | 종양 용해 백시니아 바이러스 병용 암 치료요법 |
-
2012
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active Active
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en not_active Ceased
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt not_active IP Right Cessation
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh not_active Expired - Fee Related
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en not_active Ceased
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778675B2 (en) | Immortalized avian cell lines and use thereof | |
| JP2019201661A5 (enExample) | ||
| JP6243333B2 (ja) | ワクシニアウィルスの生成のための方法および組成物 | |
| JP2012507270A5 (enExample) | ||
| JP2016105737A5 (enExample) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| JP2004501647A5 (enExample) | ||
| JP2013507935A5 (enExample) | ||
| CN104087613B (zh) | 基于aav‑itr的基因表达微载体及其构建方法和应用 | |
| JP2025169249A5 (enExample) | ||
| Zhang et al. | Insights into leghorn male hepatocellular cells response to fowl adenovirus serotype 4 infection by transcriptome analysis | |
| EP4488367A1 (en) | Rhabdovirus negative spodoptera frugiperda insect cell strain, screening therefor, identification thereof and use thereof | |
| CN111218477A (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| Bratt et al. | Genetics and paragenetic phenomena of paramyxoviruses | |
| CN112891527B (zh) | 非洲猪瘟病毒i226r基因的应用 | |
| Pelz et al. | Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus | |
| Yan et al. | Identification, functional analysis, and clinical applications of defective viral genomes | |
| Grose et al. | Purification and molecular anatomy of the varicella-zoster virion. | |
| JP2022508156A5 (enExample) | ||
| MEDEOT et al. | Heterogeneity and stability characteristics of Candid 1 attenuated strain of Junin virus | |
| CN111662883A (zh) | 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒 | |
| Saghi et al. | Biochemical characterization of temperature-sensitive rabies virus mutants | |
| CN104774873A (zh) | 一种体外组装草鱼呼肠孤病毒制备方法 | |
| CN116162599B (zh) | GSK3β在增强塞内卡病毒复制用于制备疫苗中的用途 |